Leber Congenital Amaurosis (LCA)
Scientists have identified multiple genetic mutations that can cause LCA. Using this information, scientists around the world are working to develop new gene therapies for LCA. Gene therapy is currently available for LCA caused by two mutations in a gene called RPE65, which accounts for about six percent of LCA cases.
Some people with LCA may also benefit from low-vision aids, including electronic, computer-based and optical aids. Orientation and mobility training, adaptive training skills, job placement and income assistance are available through community resources.
UCSF Health medical specialists have reviewed this information. It is for educational purposes only and is not intended to replace the advice of your doctor or other health care provider. We encourage you to discuss any questions or concerns you may have with your provider.
Seeking care at UCSF Health